Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

487
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
487
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Amyloid Fibrils03:03

Amyloid Fibrils

9.3K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
9.3K
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

489
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
489
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

166
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
166

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Astrocytic lipid dysregulation as an early driver of neurodegeneration.

Nature reviews. Neurology·2026
Same author

tRNA-derived fragments are elevated in the aging brain and may contribute to neurodegeneration.

bioRxiv : the preprint server for biology·2026
Same author

CRYAB is compromised in pathologically affected oligodendrocytes in multiple system atrophy.

Brain pathology (Zurich, Switzerland)·2026
Same author

Reduced serum interleukin-2 associates with higher motor severity and along with CD4 T cell alterations may be an early event in isolated REM Sleep Behaviour Disorder.

Brain, behavior, & immunity - health·2026
Same author

Ultra-rare variants in LAMA2 are risk factors for frontotemporal dementia and motor neuron disease.

Human molecular genetics·2026
Same author

Location and mapping of the human rostromedial tegmental nucleus and associated midbrain inhibitory nuclei regulating dopamine neurons.

Brain structure & function·2026

Related Experiment Video

Updated: Jun 10, 2025

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

17.3K

Multiple System Atrophy: Pathology, Pathogenesis, and Path Forward.

Alain Ndayisaba1,2,3, Glenda M Halliday4,5,1, Vikram Khurana2,6,3,1,7

  • 1Aligning Science Across Parkinson's Collaborative Research Network, Chevy Chase, Maryland, USA.

Annual Review of Pathology
|October 15, 2024
PubMed
Summary

Multiple system atrophy (MSA) is a fatal neurodegenerative disease. Research explores whether it originates in oligodendroglia or neurons, considering distinct alpha-synuclein structures in MSA patients.

Keywords:
alpha-synucleinalpha-synucleinopathymultiple system atrophymyelinneuroinflammationoligodendrocyte

More Related Videos

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

9.6K
Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

10.5K

Related Experiment Videos

Last Updated: Jun 10, 2025

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

17.3K
ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

9.6K
Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

10.5K

Area of Science:

  • Neurodegenerative diseases
  • Oligodendroglial biology
  • Synucleinopathies

Background:

  • Multiple system atrophy (MSA) is a fatal neurodegenerative disorder.
  • Characterized by autonomic failure and motor impairment.
  • Hallmark pathology includes oligodendroglial cytoplasmic inclusions of aggregated alpha-synuclein (αSyn).

Purpose of the Study:

  • To review evidence supporting MSA as an oligodendroglial synucleinopathy.
  • To consider emerging data suggesting primary neuronal or immune dysfunction.
  • To contextualize findings within recent discoveries of distinct αSyn conformations in MSA.

Main Methods:

  • Review of existing evidence on MSA pathology and pathogenesis.
  • Consideration of emerging data from various research domains.
  • Discussion of novel epidemiological, genetic, and molecular pathology techniques.

Main Results:

  • Evidence supports MSA as an oligodendroglial synucleinopathy, with early myelin loss.
  • Emerging data suggest potential primary roles for neuronal or immune dysfunction.
  • Alpha-synuclein (αSyn) conformation is distinct in MSA compared to other synucleinopathies.

Conclusions:

  • MSA pathogenesis remains complex, with ongoing debate about primary cellular origins.
  • Distinct αSyn conformations offer new avenues for understanding disease mechanisms.
  • Future research using advanced modeling (e.g., pluripotent stem cells) is crucial.